Dianthus (DNTH) Q2 Loss Widens 80%

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share (GAAP) was $(0.88). GAAP revenue was $0.2 million for Q2 2025. With significant increases in both research and administrative costs, the company ended the period well-capitalized but still years from potential commercialization. This quarter highlighted clinical progress alongside rising expenses and a continued focus on upcoming study milestones, providing important context for investors following the company’s path through late-stage trials. Source: Analyst estimates for the quarter provided by FactSet. Dianthus Therapeutics is advancing therapies for severe autoimmune and neuromuscular diseases. Its main focus is claseprubart, a monoclonal antibody treatment targeting the classical complement pathway for conditions like generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool